Clinical Trial Update: The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating topical mesalazine sustained-release tablets for Crohn's disease with oral ulcers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Oral Ulcer

Drugs mentioned

• Topical mesalazine sustained-release tablets (mesalazine (5-aminosalicylic acid))

Snippet

Sponsor: Xijing Hospital of Digestive Diseases | Conditions: Crohn's Disease, Oral Ulcer | Phase 3 | Status: WITHDRAWN